Vivian Hook

Vivian Hook

Auto-generated profile, based on publicly available information

Vivian Hook

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, United States

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
VHVivian Hook
Vivian Hook
LFLydiane Funkelstein
Lydiane Funkelstein
DLDouglas Lu
Douglas Lu
SBSteven Bark
Steven Bark
JWJill Wegrzyn
Jill Wegrzyn
SHShin-Rong Hwang
Shin-Rong Hwang
Peptide neurotransmitters and peptide hormones, collectively known as neuropeptides, are required for cell-cell communication in neurotransmission and for regulation of endocrine functions. Neuropeptides are synthesized from protein precursors (termed proneuropeptides or prohormones) that require proteolytic processing primarily within secretory vesicles that store and secrete the mature neuropeptides to control target cellular and organ systems. This review describes interdisciplinary strategies that have elucidated two primary protease pathways for prohormone processing consisting of the cysteine protease pathway mediated by secretory vesicle cathepsin L and the well-known subtilisin-like proprotein convertase pathway that together support neuropeptide biosynthesis. Importantly, this review discusses important areas of current and future biomedical neuropeptide research with respect to biological regulation, inhibitors, structural features of proneuropeptide and protease interactions, and peptidomics combined with proteomics for systems biological approaches. Future studies that gain in-depth understanding of protease mechanisms for generating active neuropeptides will be instrumental for translational research to develop pharmacological strategies for regulation of neuropeptide functions. Pharmacological applications for neuropeptide research may provide valuable therapeutics in health and disease.

1 March 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
VHVivian Y.H. Hook
Vivian Y.H. Hook
MKMark Kindy
Mark Kindy
GHGregory Hook
Gregory Hook
Elucidation of Abeta-lowering agents that inhibit processing of the wild-type (WT) beta-secretase amyloid precursor protein (APP) site, present in most Alzheimer disease (AD) patients, is a logical approach for improving memory deficit in AD. The cysteine protease inhibitors CA074Me and E64d were selected by inhibition of beta-secretase activity in regulated secretory vesicles that produce beta-amyloid (Abeta). The regulated secretory vesicle activity, represented by cathepsin B, selectively cleaves the WT beta-secretase site but not the rare Swedish mutant beta-secretase site. In vivo treatment of London APP mice, expressing the WT beta-secretase site, with these inhibitors resulted in substantial improvement in memory deficit assessed by the Morris water maze test. After inhibitor treatment, the improved memory function was accompanied by reduced amyloid plaque load, decreased Abeta40 and Abeta42, and reduced C-terminal beta-secretase fragment derived from APP by beta-secretase. However, the inhibitors had no effects on any of these parameters in mice expressing the Swedish mutant beta-secretase site of APP. The notable efficacy of these inhibitors to improve memory and reduce Abeta in an AD animal model expressing the WT beta-secretase APP site present in the majority of AD patients provides support for CA074Me and E64d inhibitors as potential AD therapeutic agents.

17 April 2020 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
VHVivian Hook
Vivian Hook
MYMichael C. Yoon
Michael C. Yoon
CMCharles Mosier
Charles Mosier
GIGen Ito
Gen Ito
SPSonia Podvin
Sonia Podvin
GHGregory Hook
Gregory Hook

1 January 2005 in Biological Chemistry
Verified
Journal Article
Closed access
PDF file
VHVivian Hook
Vivian Hook
TTThomas Toneff
Thomas Toneff
MBMatthew Bogyo
Matthew Bogyo
DGDoron Greenbaum
Doron Greenbaum
KMKatalin F. Medzihradszky
Katalin F. Medzihradszky
TRTerry Reisine
Terry Reisine
The regulated secretory pathway of neurons is the major source of extracellular Aβ that accumulates in Alzheimer's disease (AD). Extracellular Aβ secreted from that pathway is generated by β-secretase processing of amyloid precursor protein (APP). Previously, cysteine protease activity was demonstrated as the major β-secretase activity in regulated secretory vesicles of neuronal chromaffin cells. In this study, the representative cysteine protease activity in these secretory vesicles was purified and identified as cathepsin B by peptide sequencing. Immunoelectron microscopy demonstrated colocalization of cathepsin B with Aβ in these vesicles. The selective cathepsin B inhibitor, CA074, blocked the conversion of endogenous APP to Aβ in isolated regulated secretory vesicles. In chromaffin cells, CA074Me (a cell permeable form of CA074) reduced by about 50% the extracellular Aβ released by the regulated secretory pathway, but CA074Me had no effect on Aβ released by the constitutive pathway. Furthermore, CA074Me inhibited processing of APP into the COOH-terminal β-secretase-like cleavage product. These results provide evidence for cathepsin B as a candidate β-secretase in regulated secretory vesicles of neuronal chromaffin cells. These findings implicate cathepsin B as β-secretase in the regulated secretory pathway of brain neurons, suggesting that inhibitors of cathepsin B may be considered as therapeutic agents to reduce Aβ in AD.

31 March 2021 in ACS Chemical Biology
Verified
Journal Article
Closed access
DMDrake M. Mellott
Drake M. Mellott
CTChien-Te Tseng
Chien-Te Tseng
ADAleksandra K Drelich
Aleksandra K Drelich
PFPavla Fajtová
Pavla Fajtová
BCBala C. Chenna
Bala C. Chenna
JMJames H. McKerrow
James H. McKerrow

2 September 2015 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
GHGregory Hook
Gregory Hook
JJJ. Steven Jacobsen
J. Steven Jacobsen
KGKenneth Grabstein
Kenneth Grabstein
MKMark Kindy
Mark Kindy
VHVivian Hook
Vivian Hook
There currently is no therapeutic drug treatment for traumatic brain injury (TBI) despite decades of experimental clinical trials. This may be because the mechanistic pathways for improving TBI outcomes have yet to be identified and exploited. As such, there remains a need to seek out new molecular targets and their drug candidates to find new treatments for TBI. This review presents supporting evidence for cathepsin B, a cysteine protease, as a potentially important drug target for TBI. Cathepsin B expression is greatly up-regulated in TBI animal models, as well as in trauma patients. Importantly, knockout of the cathepsin B gene in TBI mice results in substantial improvements of TBI-caused deficits in behavior, pathology, and biomarkers, as well as improvements in related injury models. During the process of TBI-induced injury, cathepsin B likely escapes the lysosome, its normal subcellular location, into the cytoplasm or extracellular matrix (ECM) where its unleashed proteolytic power causes destruction via necrotic, apoptotic, autophagic, and activated glia-induced cell death, together with ECM breakdown and inflammation. Significantly, chemical inhibitors of cathepsin B are effective for improving deficits in TBI and related injuries including ischemia, cerebral bleeding, cerebral aneurysm, edema, pain, infection, nephritis, epilepsy, rheumatoid arthritis, pancreatitis, Huntington’s disease, and Alzheimer’s disease. The inhibitor E64d shows prominent efficacy for amelioration of TBI-caused deficits in preclinical models. In clinical trials, E64d has been shown to be safe based on its toxicological profile and, thus, illustrates the compound as an excellent candidate for drug development. These data support the overall conclusion that drug development of cathepsin B inhibitors, with E64d or a novel analog as a lead drug candidate, should be accelerated to improve the outcomes of TBI and related injuries.